Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emblem Corp EMMBF

Healthcare Biotechnology Cannabis
"Emblem Corp is a licensed producer of medical cannabis. It is intended to cultivate and cure cannabis for medicinal use. The group operates in the business segment of production and sale of medical cannabis."


OTCPK:EMMBF - Post by User

Emblem Corp > cancel this terrible bought deal
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(7)
•••
Comment by spasticatedon Nov 13, 2017 2:41pm
135 Views
Post# 26953362

RE:cancel this terrible bought deal

RE:cancel this terrible bought deallol hopefully that's what they're doing.. it was pretty foolish to set the ceiling of themselves at 1.75.. talk about setting the bar low for investors. had they not done the bought deal i guarantee the stock would be well over 2.00 right now. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities